MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics Total Shareholders Equity 2011-2026 | OGEN
Annual Total Shareholders Equity Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.28 M | -212 K | 3.17 M | 13 M | 26.5 M | 16.8 M | 17.2 M | 20.9 M | 6.32 M | 2.97 M | 4.73 M | 10.3 M | 15.8 M | 9.23 M | -8.18 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 26.5 M | -8.18 M | 9.8 M |
Quarterly Total Shareholders Equity Oragenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.83 M | -2.13 M | 138 K | -212 K | 3.08 M | 1.33 M | 2.63 M | 3.17 M | 6.5 M | 7.26 M | 10.2 M | 13 M | 15.3 M | 18.7 M | 22 M | 26.5 M | 28.5 M | 32.7 M | 36.1 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 6.32 M | 6.32 M | 6.32 M | 6.32 M | 2.97 M | 2.97 M | 2.97 M | 2.97 M | 4.73 M | 4.73 M | 4.73 M | 4.73 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 9.23 M | 9.23 M | 9.23 M | 9.23 M | -8.18 M | -8.18 M | -8.18 M | -8.18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.1 M | -8.18 M | 10.5 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.85 | 3.24 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 322.18 | -3.36 % | $ 42.2 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 4.71 | -0.53 % | $ 766 M |  Britain |
 |
Cabaletta Bio
CABA
|
112 M | $ 3.51 | 3.09 % | $ 353 M | USA |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
53.5 M | $ 7.72 | 4.04 % | $ 76.3 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 22.0 | 1.48 % | $ 1.03 B | USA |
 |
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 101.75 | 2.29 % | $ 27.2 B | Germany |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
-128 M | $ 2.25 | -12.11 % | $ 144 M | USA |
 |
ContraFect Corporation
CFRX
|
-11.9 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
32.6 M | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
6.72 B | $ 8.6 | -1.04 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.28 | 0.94 % | $ 458 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 23.69 | -3.64 % | $ 3.01 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.59 | 6.71 % | $ 423 M | Britain |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
|
Immatics N.V.
IMTX
|
87.4 M | $ 10.8 | -1.86 % | $ 679 M | Germany |
 |
Caladrius Biosciences
CLBS
|
29.6 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
-15.9 M | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 33.63 | -0.72 % | $ 2.23 B | USA |